{"id":54697,"date":"2023-03-09T20:03:06","date_gmt":"2023-03-09T19:03:06","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/haymarket-media-acquires-the-american-journal-of-endocannabinoid-medicine\/"},"modified":"2023-03-09T20:03:06","modified_gmt":"2023-03-09T19:03:06","slug":"haymarket-media-acquires-the-american-journal-of-endocannabinoid-medicine","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/haymarket-media-acquires-the-american-journal-of-endocannabinoid-medicine\/","title":{"rendered":"Haymarket Media Acquires the American Journal of Endocannabinoid Medicine"},"content":{"rendered":"
\n

\nThe acquisition expands the medical community\u2019s access to <\/i>high-quality, trusted, peer-reviewed content on cannabinoid-based therapy.<\/i>\n<\/p>\n

<\/a><\/p>\n

NEW YORK–(BUSINESS WIRE)–Haymarket Media, Inc. is pleased to announce that it has acquired the American Journal of Endocannabinoid Medicine (AJEM)<\/i><\/a>\u2014a peer-reviewed journal focused on cannabinoid medicine. Haymarket is making an additional investment in AJEM<\/i> to increase its engagement with healthcare professionals (HCPs) and fulfill its mission to educate and inform the medical community on cannabinoid-based therapy.\n<\/p>\n

\nPhysicians are not trained in the endocannabinoid system (ECS) in medical school. Yet, they are increasingly tasked with caring for patients using cannabinoid-based medicine\u2014often in conjunction with other pharmaceuticals. AJEM<\/i> <\/i>fills this knowledge gap and provides the medical community widespread access to high-quality, trusted, peer-reviewed content.\n<\/p>\n

\n\u201cIt was important for us to find the right partner to continue AJEM\u2019s <\/i>journey,\u201d says Ken Watkins, Brand Director of AJEM. <\/i>\u201cHaymarket\u2019s healthcare presence allows us to broaden our reach and offer content to physicians in a way that is familiar to them, and in a language that they speak\u2014the language of science. We are committed to publishing the latest peer-reviewed research and medical education on the endocannabinoid system as a therapeutic target,\u201d says Watkins, who founded and launched AJEM <\/i>in 2019.\n<\/p>\n

\n\u201cAdding a peer-reviewed medical cannabis journal to our portfolio reinforces our commitment to educating physicians and positions Haymarket for leadership in this emerging therapeutic area,\u201d says Lee Maniscalco, CEO of Haymarket Media, Inc.\n<\/p>\n

\nAJEM <\/i>joins the Haymarket Medical Network<\/a> (HMN) and will benefit from the division\u2019s digital expertise in delivering relevant and timely clinical content to a broad audience of HCPs. \u201cThe future of this therapeutic pathway is bright and I am excited that Haymarket will provide clinicians the opportunity to engage with evidence-based research on cannabinoid medicine,\u201d says Mike Graziani, President of Haymarket\u2019s Medical Communications Group.\n<\/p>\n

\n\u201cI am delighted to be a part of such an intelligent, collaborative effort. Haymarket\u2019s resources will allow us to finally provide much-needed endocannabinoid education to those on the front lines of medicine,\u201d says Leslie Apgar, MD, Editor-in-Chief of AJEM<\/i>.\n<\/p>\n

\nFor more information or sponsorship opportunities, contact Ken Watkins, Brand Director. For manuscript submissions, contact Meg Block Roloff, MPH, Senior Managing Editor.\n<\/p>\n

\nAbout the American Journal of Endocannabinoid Medicine<\/i><\/b>\n<\/p>\n

\nThe American Journal of Endocannabinoid Medicine\u2019s<\/i> (AJEM<\/i>) mission is to educate healthcare professionals on medicines that engage with the endocannabinoid system (ECS). By presenting clinical research on the role of the ECS in achieving homeostasis and as a therapeutic target,<\/i> AJEM <\/i>seeks to improve the practice of evidence-based cannabinoid medicine. AJEM<\/i> publishes peer-reviewed original research manuscripts and research interpretation, news, and opinion pieces from thought leaders in the field. AJEM\u2019s <\/i>renowned Editorial Board members assist in the peer-review process and are a diverse group of experts with experience in various cannabinoid medicine disciplines. To learn more, visit www.ajendomed.com<\/a>.\n<\/p>\n

\nAbout Haymarket Medical Network<\/b>\n<\/p>\n

\nHaymarket Medical Network reaches healthcare practitioners through a multichannel environment with more than 20 unique brands offered across multiple formats\u2014web, app, print, and live events. Its interconnectivity allows users to move from brand to brand to discover the relevant content they need to make practice-related decisions. The network includes renowned drug database MPR<\/i> and an expanding portfolio of websites that deliver valuable content covering specific therapeutic areas such as Cardiology Advisor<\/i>, Neurology Advisor, Infectious Disease Advisor<\/i> and Cancer Therapy Advisor<\/i>. <\/i>To learn more, visit www.haymarketmedicalnetwork.com<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nKen Watkins, Brand Director
\n
ken.watkins@haymarketmedia.com<\/a><\/p>\n

Meg Block Roloff, MPH, Senior Managing Editor
\n
megan.roloff@haymarketmedia.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

The acquisition expands the medical community\u2019s access to high-quality, trusted, peer-reviewed content on cannabinoid-based therapy. NEW YORK–(BUSINESS WIRE)–Haymarket Media, Inc. is pleased to announce that it has acquired the American Journal of Endocannabinoid Medicine (AJEM)\u2014a peer-reviewed journal focused on cannabinoid medicine. Haymarket is making an additional investment in AJEM to increase its engagement with healthcare … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-54697","6":"format-standard","7":"category-industry"},"yoast_head":"\nHaymarket Media Acquires the American Journal of Endocannabinoid Medicine - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/haymarket-media-acquires-the-american-journal-of-endocannabinoid-medicine\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Haymarket Media Acquires the American Journal of Endocannabinoid Medicine - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"The acquisition expands the medical community\u2019s access to high-quality, trusted, peer-reviewed content on cannabinoid-based therapy. NEW YORK–(BUSINESS WIRE)–Haymarket Media, Inc. is pleased to announce that it has acquired the American Journal of Endocannabinoid Medicine (AJEM)\u2014a peer-reviewed journal focused on cannabinoid medicine. Haymarket is making an additional investment in AJEM to increase its engagement with healthcare ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/haymarket-media-acquires-the-american-journal-of-endocannabinoid-medicine\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-03-09T19:03:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230309005712\/en\/1735055\/21\/HMN_RGB_FINAL_v2.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/haymarket-media-acquires-the-american-journal-of-endocannabinoid-medicine\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/haymarket-media-acquires-the-american-journal-of-endocannabinoid-medicine\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Haymarket Media Acquires the American Journal of Endocannabinoid Medicine\",\"datePublished\":\"2023-03-09T19:03:06+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/haymarket-media-acquires-the-american-journal-of-endocannabinoid-medicine\\\/\"},\"wordCount\":596,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/haymarket-media-acquires-the-american-journal-of-endocannabinoid-medicine\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230309005712\\\/en\\\/1735055\\\/21\\\/HMN_RGB_FINAL_v2.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/haymarket-media-acquires-the-american-journal-of-endocannabinoid-medicine\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/haymarket-media-acquires-the-american-journal-of-endocannabinoid-medicine\\\/\",\"name\":\"Haymarket Media Acquires the American Journal of Endocannabinoid Medicine - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/haymarket-media-acquires-the-american-journal-of-endocannabinoid-medicine\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/haymarket-media-acquires-the-american-journal-of-endocannabinoid-medicine\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230309005712\\\/en\\\/1735055\\\/21\\\/HMN_RGB_FINAL_v2.jpg\",\"datePublished\":\"2023-03-09T19:03:06+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/haymarket-media-acquires-the-american-journal-of-endocannabinoid-medicine\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/haymarket-media-acquires-the-american-journal-of-endocannabinoid-medicine\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/haymarket-media-acquires-the-american-journal-of-endocannabinoid-medicine\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230309005712\\\/en\\\/1735055\\\/21\\\/HMN_RGB_FINAL_v2.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230309005712\\\/en\\\/1735055\\\/21\\\/HMN_RGB_FINAL_v2.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/haymarket-media-acquires-the-american-journal-of-endocannabinoid-medicine\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Haymarket Media Acquires the American Journal of Endocannabinoid Medicine\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Haymarket Media Acquires the American Journal of Endocannabinoid Medicine - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/haymarket-media-acquires-the-american-journal-of-endocannabinoid-medicine\/","og_locale":"en_US","og_type":"article","og_title":"Haymarket Media Acquires the American Journal of Endocannabinoid Medicine - Pharma Trend","og_description":"The acquisition expands the medical community\u2019s access to high-quality, trusted, peer-reviewed content on cannabinoid-based therapy. NEW YORK–(BUSINESS WIRE)–Haymarket Media, Inc. is pleased to announce that it has acquired the American Journal of Endocannabinoid Medicine (AJEM)\u2014a peer-reviewed journal focused on cannabinoid medicine. Haymarket is making an additional investment in AJEM to increase its engagement with healthcare ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/haymarket-media-acquires-the-american-journal-of-endocannabinoid-medicine\/","og_site_name":"Pharma Trend","article_published_time":"2023-03-09T19:03:06+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230309005712\/en\/1735055\/21\/HMN_RGB_FINAL_v2.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/haymarket-media-acquires-the-american-journal-of-endocannabinoid-medicine\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/haymarket-media-acquires-the-american-journal-of-endocannabinoid-medicine\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Haymarket Media Acquires the American Journal of Endocannabinoid Medicine","datePublished":"2023-03-09T19:03:06+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/haymarket-media-acquires-the-american-journal-of-endocannabinoid-medicine\/"},"wordCount":596,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/haymarket-media-acquires-the-american-journal-of-endocannabinoid-medicine\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230309005712\/en\/1735055\/21\/HMN_RGB_FINAL_v2.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/haymarket-media-acquires-the-american-journal-of-endocannabinoid-medicine\/","url":"https:\/\/pharma-trend.com\/en\/haymarket-media-acquires-the-american-journal-of-endocannabinoid-medicine\/","name":"Haymarket Media Acquires the American Journal of Endocannabinoid Medicine - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/haymarket-media-acquires-the-american-journal-of-endocannabinoid-medicine\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/haymarket-media-acquires-the-american-journal-of-endocannabinoid-medicine\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230309005712\/en\/1735055\/21\/HMN_RGB_FINAL_v2.jpg","datePublished":"2023-03-09T19:03:06+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/haymarket-media-acquires-the-american-journal-of-endocannabinoid-medicine\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/haymarket-media-acquires-the-american-journal-of-endocannabinoid-medicine\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/haymarket-media-acquires-the-american-journal-of-endocannabinoid-medicine\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230309005712\/en\/1735055\/21\/HMN_RGB_FINAL_v2.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230309005712\/en\/1735055\/21\/HMN_RGB_FINAL_v2.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/haymarket-media-acquires-the-american-journal-of-endocannabinoid-medicine\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Haymarket Media Acquires the American Journal of Endocannabinoid Medicine"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/54697","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=54697"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/54697\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=54697"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=54697"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=54697"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}